Sphingolipid-modulated Exosome Secretion Promotes Clearance of Amyloid-β by Microglia

Kohei Yuyama, Hui Sun, Susumu Mitsutake, and Yasuyuki Igarashi

From the Department of Biomembrane and Biofunctional Chemistry, Faculty of Advanced Life Science, Hokkaido University, Sapporo 001-0021, Japan

Background: Exosome is a membrane vesicle released from several types of cells, including neurons.

Results: Neuronal exosomes accelerate Aβ fibril formation, and the exosome-associated Aβ is taken into microglia to degrade it.

Conclusion: Exosomes promote Aβ clearance.

Significance: These findings provide a new function of exosome in the brain and also suggest its involvement in the development of Alzheimer disease.

Amyloid-β-peptide (Aβ), the pathogenic agent of Alzheimer disease, is a physiological metabolite whose levels are constantly controlled in normal brain. Recent studies have demonstrated that a fraction of extracellular Aβ is associated with exosomes, small membrane vesicles of endosomal origin, although the fate of Aβ in association with exosome is largely unknown. In this study, we identified novel roles for neuron-derived exosomes acting on extracellular Aβ, i.e. exosomes drive conformational changes in Aβ to form nontoxic amyloid fibrils and promote uptake of Aβ by microglia. The Aβ internalized together with exosomes was further transported to lysosomes and degraded. We also found that blockade of phosphatidylserine on the surface of exosomes by annexin V not only prevented exosome incorporation into microglia. In addition, we demonstrated that secretion of neuron-derived exosomes was modulated by the activities of sphingolipid-metabolizing enzymes, including neutral sphingomyelinase 2 (nSMase2) and sphingomyelin synthase 2 (SMS2). In transwell experiments, up-regulation of exosome secretion from neuronal cells by treatment with SMS2 siRNA enhanced Aβ uptake into microglial cells and significantly decreased extracellular levels of Aβ. Our findings indicate a novel mechanism responsible for clearance of Aβ through its association with exosomes. The modulation of the vesicle release and/or elimination may alter the risk of AD.

Alzheimer disease (AD) is a late-onset neurological disorder with progressive loss of memory and cognitive ability as a result of neuronal impairment and death. AD is pathologically featured by extensive extraneuronal deposition of amyloid fibrils, which are composed of amyloid β protein (Aβ). The Aβ is generated by the processing of amyloid precursor protein (APP) as a physiological metabolite and is subsequently secreted to extracellular milieu. Steady-state levels of extracellular Aβ are controlled by the balance between its generation and its degradation/clearance. Several lines of evidence indicate that Aβ accumulation, attributable to an imbalance of its metabolism, is linked to the pathogenesis of AD. In the case of familial AD, genetic alterations of certain genes, such as APP and presenilin, appear to facilitate Aβ assembly through a marked enhancement in Aβ production. In contrast, in sporadic AD, a common form of the disease, the decreased level of Aβ elimination within the brains is apparent. This suggests a perturbation of Aβ clearance through, for example, decreased catabolism via reduced proteolysis or impaired efflux across the blood-brain barrier into CSF. However, the precise clearance process, which appears damaged in AD, remains controversial.

In a recent report, a portion of extracellular Aβ was found to be associated with membrane vesicles called exosomes. Exosomes represent a specific subtype of secreted small vesicles (40–100 nm in diameter) derived from various types of cells, including neurons. They correspond to the intraluminal vesicles of endosomal multivesicular bodies (MVBs) that fuse with the plasma membrane in an exocytic manner. A well-known function of exosomes is to remove obsolete or misfolded proteins and to secrete them into a drainage system, such as the gut or urinary tract. In addition, accumulated evidence has indicated that exosomes act as shuttles for intercellular delivery of cargo, including specific proteins, lipids, and RNAs. The exosome marker Alix has been observed in Aβ plaques in the AD brain. Our previous study also demonstrated that PC12-derived exosomes potentially promote Aβ fibrillogenesis, under endocytic impairment, which is apparent with the early pathological changes in AD brains.

With these lines of evidence in mind, we investigated the fate of extracellular Aβ associated with exosomes. We demonstrated that exosomes were constitutively released from neuroblastoma N2a cells and mouse primary cortical neurons. These exosomes significantly accelerated amyloidogenesis of Aβ from its soluble form. Notably, the neuron-derived exosomes were incorporated into microglia, resulting in enhanced Aβ uptake.

1 To whom correspondence should be addressed. Tel: 81-11-706-9001; Fax: 81-11-706-9047; E-mail: yigarash@pharm.hokudai.ac.jp.

2 The abbreviations used are: AD, Alzheimer disease; Aβ, amyloid β protein; APP, amyloid precursor protein; nSMase, neutral sphingomyelinase; aSMase, acid sphingomyelinase; Cer, ceramide; THT, thioflavin T; D609, tricyclodecan-9-xanthogenate; AV, annexin V; MVB, multivesicular body; CTB, cholera toxin B; EGCas, endoglycoceramidase; PS, phosphatidylserine; GSL, glycosphingolipid; FAM, carboxyfluorescein-conjugated human Aβ.
Exosome-mediated Aβ Clearance

and degradation by the microglia. Moreover, we determined that secretion of the exosomes was regulated by specific sphingolipid-metabolizing enzymes. Up-regulation of the exosome secretion, which is mediated by sphingomyelin synthase 2 (SMS2) siRNA, was sufficient for inducing the enhancement of Aβ uptake by microglia and resulted in a significant reduction of extracellular Aβ in transwell co-cultures of neuronal and microglial cells. These results imply the existence of novel machinery active in Aβ clearance mediated by exosomes.

EXPERIMENTAL PROCEDURES

Antibodies and Reagents—Primary antibodies were obtained from the following suppliers: mouse monoclonal antibodies against Alix, BiP, GM130 (BD Biosciences); Aβ (Signet, Dedham, MA); rabbit polyclonal antibodies against Tsg-101 (Santa Cruz Biotechnology, Santa Cruz, CA); and Aβ oligomer (Invitrogen). Secondary antibodies were from GE Healthcare. Thioflavin T (ThT), cholera toxin B subunit (CTB), HRP-conjugated CTB, annexin V (AV), imipramine, GW4869, D609, bacterial SMase (Staphylococcus aureus), and endoglycoceramidase (EGCase) II with activator II were obtained from Sigma. AlexaFluor594-conjugated CTB, AlexaFluor488-conjugated (EGCase) II with activator II were obtained from Sigma. AlexaFluor594-conjugated CTB, AlexaFluor488-conjugated AV, and LysoTracker Green DND-26 and Blue DND-22 were purchased from Invitrogen. N-Hexanoyl-β-erythro sphingosine (d18:1/6:0) was from Avanti Polar Lipids (Alabaster, AL). The isolated cerebral cortices of mouse brains on embryonic day 15, according to the manufacturer’s protocol.

Cell Cultures—Neuro2a mouse neuroblastoma cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum. The murine microglial cell line BV-2 was purchased from National Cancer Institute (Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy) and cultured in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum and L-glutamine.

Primary cultures of neurons were prepared from the cerebral cortices of mouse brains on embryonic day 15, according to the methods of Levi et al. (10). Briefly, neurons were prepared from the isolated cerebral cortices using a dissociation solution (Sumitomo Bakelite, Tokyo, Japan). The cells were plated onto a polyethyleneimine (PEI)-coated dish at a density of 5.0 × 10^5 cells/cm^2 and cultured in neurobasal medium (Invitrogen) with 25 mM KCl, 2 mM glutamine, and B27 supplement (Invitrogen). After plating, the cells were cultured for 7 days and then used for assays. Primary microglia prepared from a newborn rat were purchased from Sumitomo Bakelite and maintained in a microglial culture medium (Sumitomo Bakelite), according to the manufacturer’s protocol.

Exosome Isolation—Exosomes were prepared from culture supernatants of N2a cells and mouse primary cortical neurons as described previously (11). One day before preparation of exosomes, cell culture medium was replaced with serum-free medium. Cell culture supernatants were collected after 24 h and sequentially centrifuged at 3,000 × g for 10 min, 4,000 × g for 10 min, and 10,000 × g for 30 min to remove cells, dead cells, and debris and then spun again at 100,000 × g for 1 h to obtain exosomes as pellets.

For sucrose gradient analysis, each exosome pellet (correspond to the amount from 5 × 10^7 cells) was loaded onto 10 ml of sucrose gradient (0.25–2.3 mM sucrose in 20 mM HEPES, 10 mM) and centrifuged at 100,000 × g for 18 h. After centrifugation, 1-ml fractions were collected, diluted with 20 mM HEPES, and precipitated by centrifugation for 1 h at 100,000 × g. The resulting pellets were resuspended in PBS and subjected to Western blot analysis.

Electron Microscopy—The 100,000 × g pellets purified from the culture supernatants of N2a cells and primary cortical neurons were resuspended in TBS and applied to a grid covered with collodion and then negatively stained with 2% phosphotungstic acid (Nisshin EM, Tokyo, Japan). Microphotographs were obtained using an HD-2000 scanning transmission electron microscope (Hitachi, Tokyo, Japan).

Seed-free Aβ Preparation—Seed-free Aβ solutions were prepared essentially according to a published report (12). Briefly, synthetic Aβ40 and Aβ42 were dissolved in 0.02% ammonia solution at 500 and 300 μM, respectively. To remove undissolved Aβ aggregates, which can act as pre-existing seeds, the prepared solutions were centrifuged at 540,000 × g for 3 h at 4°C. The obtained supernatants were collected and stored at −80°C until use.

EGCase Treatment and CTB Binding—N2a-derived exosome pellets were resuspended in PBS containing 20 mM HEPES (pH 7.4) and treated with 25 milliunits of EGCase for 15 h or 1 μM CTB for 1 h at 37°C. Then the exosomes were precipitated again by ultracentrifugation at 100,000 × g for 1 h and used for ThT assay.

Thioflavin T Assay—Seed-free Aβ solutions (25 μM) were incubated at 37°C in 100 μl of TBS containing 0, 1, or 10 μl of exosome solutions. One microliter of exosome solution was incubated in 100 μl of TBS with or without exosomes (100,000 × g pellets) for various times at 37°C. The mixtures were then dotted onto a nitrocellulose membrane, and the membrane was incubated with primary antibodies against Aβ oligomer (A11) and Aβ (6E10) and then with HRP-conjugated secondary antibodies. Chemiluminescence was detected and analyzed using a combination of an ECL Plus Kit (GE Healthcare), and a LAS4000 imager (Fuji Film, Tokyo, Japan).

Toxicity Assay—Seed-free solutions of Aβ42 (25 μM) were incubated in 100 μl of TBS with or without exosomes (100,000 × g pellets) for 5 h at 37°C in 100 μl of neurobasal medium supplemented with 25 mM KCl, 2 mM glutamine, and B27 supplement. The preincubated mixtures were applied to the primary cortical neurons that had been plated on 24-well plates and incubated for 24 h. The cell viabilities were determined using WST-1 cell viability assay kit (Dojindo, Kumamoto, Japan) and LIVE/DEAD® cell viability kit (Invitrogen).
Drug Treatment—The treatment with imipramine (10 μM), GW4869 (10 μM), D609 (50 μM), N-hexanol-d-erythrosphingosine (50 μM), or bacterial Smase (100 microm units/ml) was performed for 24 h in serum-free medium.

siRNA Delivery and Transfection—For RNA-mediated interference (RNAi) experiments, we used Stealth RNAi Transfection reagent (Invitrogen) according to the manufacturer’s protocol. Transient transfection was performed using a Lipofectamine2000 kit (Invitrogen) according to the manufacturer’s protocol.

siRNA for nSMase2 or SMS2, using a Lipofectamine2000 kit. After 24 h, inserts were placed onto wells containing BV-2 cells. After an additional 24 h of incubation, the levels of Aβ in the medium were determined by ELISA. Intracellular Aβ levels in BV-2 cells were also measured using ELISA following solubilization in guanidine HCl buffer, as described above.

RESULTS

Neuron-derived Exosomes Drive Aβ to Form Amyloid Fibrils—Culture medium from N2a cells or primary cortical neurons was subjected to successive centrifugation steps with increasing centrifugal forces, eventually providing a 100,000 × g pellet. Electron microscopy analysis revealed that the pellet, collected from the N2a cultures, mainly consisted of small membrane vesicles of ~40–100 nm diameter (Fig. 1B), similar to previously described exosome preparations (16). The pellet was separated by a continuous sucrose density gradient, and the exosomal proteins, Alix and Tsg101, were detected in fractions 4 and 5 (corresponding to a sucrose density of 1.12 and 1.16 g/ml, Fig. 1A), similar to reports from others (6). Exosomes are reportedly enriched in the proteins and lipids, associated with lipid microdomains (17). The ganglioside GM1, a glycosphingolipid abundant in lipid microdomains, was also detected in high concentrations in the same fractions as Alix and Tsg101. In contrast, BiP and GM130, marker proteins for endoplasmic reticulum and for Golgi respectively, were not found in the 100,000 × g pellet. The pellets collected from the primary neuronal cultures also contained membrane vesicles of similar size and densities, and bearing Alix, Tsg101, and GM1 (data not shown). These data confirm that the 100,000 × g pellet mainly consists of exosomes and demonstrate that the exosomes are secreted from N2a and primary cortical neurons in a constitutive manner.

To examine the effect of neuron-derived exosomes on Aβ conformational transition, we mixed the resulting pellets of the sequential centrifugation steps (P3, P4, P10, and P100) with soluble Aβ40 and Aβ42, two major species of Aβ, and incubated the mixture at 37 °C for 24 h. The amount of amyloid fibrils was then determined using ThT. As a result, ThT fluorescence intensities were significantly enhanced by only in the presence of P100, the exosome fraction (Fig. 1C). Both N2a- and primary neuron-derived exosomes significantly accelerated the fibril formations of Aβ40 and Aβ42 in a time-dependent fashion (Fig. 1D). The fluorescence of ThT follows a characteristic sigmoidal curve when Aβ was incubated at 37 °C (12). As Aβ42 has higher aggregate-prone property, Aβ42 reached a plateau more rapidly than Aβ40. In Aβ42, the amounts of amyloid Aβ significantly increased after reaching a plateau phase.

Accumulated lines of evidence indicate that glycosphingolipids (GSLs), especially gangliosides, serve as a template for Aβ assembly (18, 19). In addition, it has been found that the Aβ-bound ganglioside GM1 has been found in brains exhibit-
FIGURE 1. Aβ amyloidogenesis by neuronal exosomes. A, exosomes were collected from the culture supernatant of Neuroblastoma N2a cells, by sequential centrifugation as indicated under “Experimental Procedures.” The 100,000 x g pellets were further subjected to sucrose gradient centrifugation, and the resulting fractions were analyzed for the exosomal proteins Alix and Tsg101 and for the GM1 ganglioside. B, purified exosomes (100,000 x g pellet) underwent negative staining with phosphotungstic acid and were examined by electron microscopy. Scale bars, right panel, 500 nm; left panel, 100 nm. C, culture medium from N2a cells was subjected to sequential centrifugation. The resulting pellets, 3,000 x g (P3), 4,000 x g (P4), 10,000 x g (P10), and 100,000 x g (P100), were mixed with soluble 25 μM seed-free soluble Aβ40 or Aβ42 and incubated for 24 h at 37 °C. Amyloid fibrils formed in the incubation mixtures were measured with a ThT assay. The indicated values for relative fluorescence (AU) are means ± S.E. D, after the indicated time of incubation, ThT fluorescence intensities were measured in mixtures containing 25 μM Aβ and the indicated amount of exosomes derived from the culture supernatant of N2a cells or cortical neurons. Values provided as the means ± S.E. are as follows: *p < 0.05; **p < 0.01; ***p < 0.001; t test. E, after CTB or EGCase treatment, the exosomes (Exo) were mixed with 25 μM Aβ and incubated at 37 °C for 5 h. Ctrl, control. Values are the means ± S.E. *p < 0.05; **p < 0.01; t test.
ing early pathological changes of AD (20). We therefore examined whether GSLs in the exosome membranes are involved in acceleration of Aβ fibrillogenesis by the exosomes. Blocking of ganglioside GM1 by CTB partially but clearly prevented Aβ fibrillization, induced by N2a-derived exosomes (Fig. 1E). Moreover, glycan cleavage by EGCase treatment almost entirely inhibited the fibril formation. These findings suggest that the sugar chains of GSLs have a role to induce Aβ fibril formation on the surface of the exosomes.

To further investigate the effect of exosomes on the formation of oligomeric Aβ, the mixtures of Aβ with or without N2a-derived exosomes were analyzed by dot blotting with the anti-oligomer antibody A11 and anti-Aβ (6E10) antibodies. As shown in Fig. 2A, the incubation mixtures were subsequently added to cortical neurons, and after 24 h, the cell viabilities were determined using a WST-1 assay (C) or LIVE/DEAD viability kit (D and E). Neurons were stained with SYTO10/RED DEADTM, showing green staining for all cells and red staining for dead cells. Scale bar, 20 μm. Data are represented as the means ± S.E. **, p < 0.01; *** p < 0.001; t test.

**Sphingolipid Metabolism Is Involved in the Exosome Secretion and Aβ Fibril Formation**—Exosomes originate from the budding of intraluminal vesicles into multivesicular endosomes. Trajkovic et al. (23) reported that sphingolipid ceramide triggers the intraluminal budding and leads to exosome release in oligodendrocytes. To investigate whether the secretion of the neuron-derived exosome can be modulated by sphingolipid metabolism, we first treated N2a cells and primary neurons with inhibitors for sphingolipid-metabolizing enzymes. The levels of released exosomes were determined by evaluating the amount of the exosomal markers, Alix, Tsg101, and GM1, in the 100,000 g pellets. GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), a neutral pH-active form of the enzyme SMase, which converts sphingomyelin to ceramide (Cer). Treatment of either cell with GW4869 significantly decreased the levels of released exosomes (Fig. 3, A and B),
Exosome-mediated Aβ Clearance

FIGURE 3. Effect of sphingolipid metabolism on exosome secretion and Aβ amyloidogenesis. A and B, N2a cells or cortical neurons were treated with imipramine, GW4869, D609, or their respective diluent for 24 h. Exosomes were then collected from the medium of each culture (5 × 10⁶ cells) and were subjected to SDS-PAGE, followed by Western blotting (WB) to detect Alix, Tsg101, and GM1 ganglioside. A, representative blots illustrating the amount of Alix in N2a cell lysates (2.5 × 10⁶ cells) and 100,000 g pellets (Exosome). B, quantification of staining in Western blots. Results shown are the means ± S.E. from two independent experiments (n = 4). *, p < 0.05; **, p < 0.01; t test.

C and D, small interfering RNAs (siRNA) active against aSMase, nSMase1, nSMase2, SMS1, and SMS2 were delivered into N2a cells. Exosomes were purified from the medium of the siRNA-treated cells as in A, and the amounts of exosome markers in the resulting pellets were determined by Western blotting. C, Alix was detected in the cell lysates and in the exosomes as in A. D, band intensities of exosomal markers were analyzed. Data are presented as the means ± S.E. from two independent experiments (n = 4). *, p < 0.05; **, p < 0.01; t test.

E, N2a cells were treated with N-hexanoyl-d-erythrospingosine (50 μM) or bacterial SMase (100 microunits/ml) for 24 h. The level of released exosomes were evaluated by Western blotting. Results are expressed as means ± S.E. (n = 3). *, p < 0.05; t test.

F, exosomes isolated from the cultures of N2a cells or primary neurons, that had been treated with the indicated inhibitors, were incubated at 37 °C with 25 μM soluble Aβ42. Aβ amyloid fibrils formed in the mixtures were measured by ThT assay. The indicated values for relative fluorescence (AU) are means ± S.E. from two independent experiments (n = 4). *, p < 0.05; **, p < 0.01; ***p < 0.001; t test.

G, exosomes isolated from the cultures of N2a cells that had been treated with the indicated siRNA were mixed with 25 μM Aβ42. After 5 h of incubation, ThT fluorescence was measured. Data are represented as the mean ± S.E. (n = 4). *, p < 0.05; t test. Ctrl, control.
consistent with the study of Trajkovic et al. (23). In contrast, the treatment with imipramine, which selectively inhibits acid sphingomyelinase (aSMase), did not affect the exosome release. D609 has been reported to inhibit sphingomyelin synthase (24), which catalyzes the conversion of Cer into SM, i.e. the opposite of SMase. Predictably, treatment with D609 significantly enhanced exosome secretion.

To further explore the role of sphingolipid metabolism in exosome secretion, we employed an RNA interference approach to knock down the expression of endogenous SMases and SMss in N2a cells. We employed siRNAs against SMS1, SMS2, aSMase, nSMase1, and nSMase2, which reduced expression of the target genes efficiently in N2a cells (~85% reduction in cells transfected with each siRNA). Again in agreement with the findings of Trajkovic et al. (23), treatment with siRNA for nSMase2 reduced exosome release from N2a cells (Fig. 3, C and D). However, following treatment with siRNA against aSMase or nSMase1, no similar reduction was observed. Conversely, knockdown of either SMS1 or SMS2 with siRNA induced significant increases in exosome secretion. Increases were especially remarkable following SMS2 knockdown compared with SMS1 knockdown (Fig. 3D). These results indicate that Cer production affects the exosome secretion, and modulations of nSMase2 and SMS can alter the levels of released exosomes from N2a cells. Indeed, exogenously added Cer and Cer production following exogenously added SMase significantly increased the release levels of the exosomes (Fig. 3E).

Next, we examined the role of sphingolipid metabolism on exosome-mediated Aβ fibrillogenesis. As described above, we collected exosomes from the culture supernatants of the cells that had been treated with inhibitors or siRNAs, and we measured the ThT fluorescence in the mixtures of the exosomes and Aβ42 after a 5-h incubation at 37 °C. When exosomes purified from GW4869- or nSMase2 siRNA-treated cultures were included in the mixture, Aβ fibrillogenesis was significantly reduced (Fig. 3, F and G). Conversely, in the presence of exosomes from D609- or SMS2 siRNA-treated cultures, amyloid formation was increased, compared with that in controls. From these combined data, we consider that the potential of the exosomes to modulate Aβ fibril formation is closely related to their relative amount. In addition, the release of exosomes can be modulated by activities of enzymes responsible for sphingolipid synthesis.

**Microglia Engulf Exosomes in a Phosphatidylserine (PS)-dependent Manner**—Microglia are the resident phagocytes in the central nervous system. It is now widely accepted that these cells are derived from macrophages and contribute to the removal of dead cells and debris in the brain (25). Several reports have revealed that macrophages also take up exosomes secreted from several different cell types to transduce inflammatory signals or its elimination (26). Recently, Fitzner et al. (27) reported that oligodendrocyte-derived exosomes are preferentially internalized by microglia in brain. To evaluate whether microglia also engulf neuronal exosomes, we applied N2a-derived exosomes labeled with the fluorescent dye PKH26 to BV-2 microglial cells, primary microglia, or primary cortical neurons. After a 3-h incubation with the labeled exosomes at 37 °C, the cells were fixed, stained with DAPI, and analyzed by confocal microscopy. We observed significant fluorescence in both BV2 cells and primary microglia (Fig. 4A). These results suggest that exosomes are efficiently internalized into microglia. In contrast, fluorescent signals were rarely detected in pri-
primary neurons, further demonstrating the selective transfer of neuron-derived exosomes into microglia.

Various cells produce exosomes expressing PS on their surface, and PS exposed on the outer leaflet of the plasma membrane of apoptotic cells is often used as a recognition signal by macrophages and microglia (15, 28). We stained N2a-derived 100,000 × g pellets with fluorescently labeled AV or CTB subunit, which specifically recognizes PS and GM1, respectively. Significant fluorescence corresponding to both AV and CTB was observed (Fig. 4B), suggesting PS was located on the outer leaflet of N2a-derived exosomes. To examine the mechanism for exosome uptake by microglia, we exposed exosomes preincubated with AV or CTB to microglial cultures. We found that treatment with AV significantly suppressed uptake of exosomes into BV-2 cells or primary microglia, although treatment with CTB had no effect (Fig. 4, C and D). These results suggest that PS facilitate for the recognition and internalization of neuronal exosomes by microglia.

**Exosomes Facilitate Aβ Clearance by Microglia**—The interaction between the exosomes and Aβ leads to accelerated Aβ fibril formation (Fig. 1, C and D), suggesting that Aβ amyloid fibrils accumulate surrounding exosomes. Indeed, the exosomal marker Alix was observed to be concentrated in the senile plaque, an extracellular deposition of Aβ fibrils, found in AD brain (5). We also confirmed that exosomes are internalized by microglia (Fig. 4A). Based on these findings, we hypothesized that the exosomes may have roles in the uptake of Aβ amyloid by microglia, aiding Aβ degradation. To test this hypothesis, we added Aβ42, preincubated with or without exosomes, to BV-2 cells or primary microglia. After incubating at 37 °C for up to 5 h, we determined the intra- and extracellular levels of Aβ42. Both BV-2 and primary microglia internalized the Aβ much more dramatically in the presence of exosomes than without (Fig. 5A). Correspondingly, the levels of Aβ in the medium gradually decreased with significant difference between the presence and absence of exosomes (Fig. 5B) 76.5 ± 2.6 and 26.6 ± 5.4% reduction of Aβ in the presence and absence of exosomes after 5 h of incubation, respectively. In contrast, the exosome could not affect the uptake of the amyloid fibrils, which had been already formed (Fig. 5C). To further examine whether the prevention of exosome uptake might affect Aβ incorporation by microglia, we blocked PS on the outer surface of exosomes by AV. As shown in Fig. 5D, the Aβ uptake was significantly suppressed when exosomes had been preincubated with AV and not when preincubated with CTB. These results suggest that exosomes can, at least partially, mediate Aβ uptake in a PS-dependent manner.

Next, to assess whether the Aβ internalized together with exosomes is degraded in microglia, we administered Aβ42, preincubated with or without the exosomes, to BV-2 cells, incubated them for 3 h, and then washed the cells. After additional culture time, cells were harvested, and the Aβ levels in the cell lysates were determined. The intracellular Aβ levels in the BV-2 cells gradually decreased in a time-dependent manner and were nearly depleted by 48 h (Fig. 6A). To gain insight into the degradation pathway of the internalized exosomes and Aβ, we investigated their localization by staining with LysoTracker, a fluorescence marker of late endosome/lysosomes. We incubated PKH26-labeled, N2a-derived exosomes with BV-2 cells for 3 h at 37 °C and examined the cells by fluorescence microscopy. Punctate fluorescence was observed in the cells and portions of the exosome fluorescence co-localized with the lysosomal compartments (Fig. 6B). We next applied a preincubated mixture of FAM-Aβ42 and labeled exosomes to BV-2 cells. Together with the exosome fluorescence, the signal corre-
sponding to Aβ also co-localized with the LysoTracker signal (Fig. 6C). These data demonstrated that the Aβ internalized in an exosome-mediated manner was delivered to lysosomes within BV-2 cells to be degraded via the endocytic pathway.

**Does Up-regulation of Exosome Secretion Affect Aβ Clearance?**—Finally, we investigated whether modulating exosome secretion can affect Aβ clearance by microglia. We plated N2a cells on transwell inserts and treated with siRNA for SMase2 or SMS2 to modulate the amount of exosomes released from the cells. We also concurrently transfected with APP to overexpress Aβ. Twenty four hours after the transfection, we set the inserts into the 24-well multiplates, on which BV-2 cells had been seeded. Under this experimental setting, we presumed that exosomes and Aβ, secreted from N2a cells, would be able to interact with the BV-2 cells through medium shared between the cells. After 24 h of co-incubation, the levels of Aβ in the medium were determined. RT-PCR showed that either nSMase2 or SMS2 siRNA efficiently decreased its target mRNA expression in N2a-APP cells (81 ± 2.7 and 86 ± 4.3% reduction in cells with nSMase2 and SMS2 siRNA treatment, respectively). When there were no BV-2 cells in the lower wells, the level of extracellular Aβ remained unchanged even in N2a-APP cells that were treated with nSMase2 or SMS2 siRNA (Fig. 7A). Several studies have been reported that sphingolipid metabolism is involved in the APP processing for generating Aβ (29). However, the knockdown of nSMase2 or SMS2 with siRNA did not affect the levels of Aβ secreted from N2a cells. In contrast, in the presence of BV-2 cells on the lower wells, the levels of both Aβ40 and Aβ42 in the culture media were significantly decreased following SMS2 siRNA treatment (Fig. 7B). In addi-
Exosome-mediated Aβ Clearance

FIGURE 7. Enhancement of Aβ clearance by SMS2 knockdown. A-C, N2a cells seeded in inserts were transfected with the APP770 and siRNA as indicated. After 24 h, the media were removed and the inserts with the N2a cells were placed into wells with (D) or without (A) BV-2 cells and cultured for another 24 h. The levels of Aβ in the medium (A and B) and in the BV-2 cells (C) were measured by ELISA. Values are means ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; t test. D, N2a cells were transfected with APP and siRNA for N-SMase2 or SMS2 for 24 h. The levels of Aβ in the medium (A and B) were measured by ELISA. Values are means ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; t test. Ctrl, control.

With the exosomes, enhancing Aβ uptake by microglia and eventually resulting in the reduction of extracellular Aβ.

DISCUSSION

In the study presented here, we found that exosomes are constitutively secreted by neurons, and the exosomes dramatically promote Aβ amyloidogenesis. Furthermore, the assembled Aβ, in association with exosomes, was further taken up by microglia for degradation. We also demonstrated that up-regulation of exosome secretion, which was induced by SMS2 knockdown, efficiently reduced extracellular levels of Aβ in a co-culture of neuronal and microglial cells. In CNS, neurons are surrounded by microglia that survey to remove damaged structures such as apoptotic cells and obsolete synaptic connections (30). This study provides new insight into the coordinating machinery between neurons and neighboring microglia using exosomes for the clearance of Aβ (see the proposed scheme, Fig. 8).

Regarding the formation of ordered Aβ aggregates, the seeding polymerization theory was previously proposed (31). In this theory, the transition of the monomeric Aβ to its polymer requires a conformational change of Aβ to act as a seed, as might be provided by condensation or interaction with other molecules (28). We found that the neuron-derived exosomes accelerate Aβ amyloidogenesis from monomeric Aβ (Fig. 1, C and D). Furthermore, cleavage of GSL glycans by EGCase inhibited acceleration of Aβ fibrillogenesis by exosomes. These data suggest that interaction between Aβ and GSL glycans leads the conformational change of Aβ. GSL glycans are also localized at Aβ aggregates, the seed for cooperative polymerization activity (32). Further detailed characterization of the exosome is needed; however, these findings raise a possibility that GSL accumulation and clustering at the exosome membrane might serve as a template for Aβ assembly. In a recent report, Aβ fibrils formed by GM1-
containing membranes exhibited toxicity toward PC12 cells (33). However, we demonstrated that addition of an exosome/Ab mixture to primary cortical cells significantly suppressed neuronal toxicity. This suppression was inversely correlated with the amount of oligomeric Ab (Fig. 2), but it had no correlation with the amount of exosome-mediated Ab fibrils (Fig. 1D). It is well known that Ab fibrils exhibit polymorphism, which depends on the differences in the first step of amyloidogenesis (34, 35). Further examination is needed to identify the mechanism behind exosome-mediated Ab fibrillogenesis.

In this study, we collected released exosomes and assessed their ability to facilitate Ab amyloidogenesis in TBS (Fig. 1, C and D) or in the culture medium (data not shown). The results suggest that the exosomes would be able to efficiently promote the formation of Ab fibrils in extracellular space. However, β-site cleavage of APP has been reported to occur in MVBS (36). In addition, Ab42 has been found to localize predominantly to MVBS in normal mouse and human brain. In addition, in a mouse model of AD and in human AD brain, Ab42 progressively accumulates in MVBS with age (37). Notably, GM1-bound Ab, an amyloid seed, is preferentially observed in endosomes of neurons from aged monkey brain (38). Thus, additional careful examinations will be required to investigate the possibility that the intraluminal space of MVB might provide another cellular milieu for Ab assembly prior to the release of exosomes and Ab.

We found that selective inhibition of nSMase2 activity reduced the exosome secretion, but inhibiting SMS2 activity increased the secretion (Fig. 3, C and D). nSMase2 is especially abundant in mammalian brains (39). It has two putative transmembrane domains at the N terminus and is mainly localized in the plasma membrane (40). SMS2 also has predicted six membrane-spanning regions, and it contributes to sphingomyelin production at the plasma membrane (41). We also found that exogenously added synthetic Cer and bacterial SMase increase exosome secretion (Fig. 3E). SMS2 apparently contributes more to exosome secretion than does SMS1, which is actually responsible for the bulk of sphingomyelin generation (Fig. 3, C and D) but is localized in the Golgi apparatus (42). Altogether, this information suggests that the elevations in the local levels of Cer, especially at the plasma membranes, including endocytosed membrane regions, would be important for the promotion of exosome generation.

Our results here support a role for Cer in exosome generation. One possible mechanism would be Cer inducing a physical alternation in the endosomal membrane that preferentially promotes the budding of intraluminal vesicles. Indeed, it has been reported that Cer can induce a coalescence of small microdomains into lager microdomains, thereby promoting domain-induced budding of plasma membranes (43). Treatment with bacterial SMase is known to induce intraluminal membrane budding from SM-containing synthetic giant liposomes (23). Alternatively, several lines of evidence suggest that Cer can also affect endocytic transport. Cer production, induced by exocytosis of aSMase, reportedly promotes endocytic transport (44). Exogenously added bacterial SMase is also known to induce ATP-independent endocytosis (45). These studies suggest another possibility that Cer might promote exosome generation by enhancing the rate of endocytosis.

Previous studies have shown that microglia can directly take up Ab itself and degrade it in lysosomal compartments (46). Thus, the functional significance of Ab incorporation together with exosomes remains unclear. One conceivable purpose would be to increase the efficiency of the Ab uptake. Ab rapidly forms amyloid fibrils in the presence of exosomes (Fig. 1, C and D), and microglia can take up Ab more promptly after the excessive production of Ab, in the presence of exosomes (Fig. 5). Furthermore, addition of exosomes suppressed the formation of toxic oligomers (Fig. 2); this would be highly effective for avoiding impairment of neurons. Another conceivable benefit of microglia incorporating Ab with exosomes would be a decrease in immunological reactions by the microglia. Accumulated evidence indicates that fibril Ab facilitates inflammatory responses in microglia, including the release of proinflammatory cytokines and reactive oxygen species (47). Activated microglia surrounding senile plaque, an excessive deposition of Ab fibrils, contribute to chronic inflammation in the AD brain. In general, it is well understood that PS-dependent ingestion of apoptotic bodies by microglia is associated with anti-inflammatory reactions (48). In addition, it has recently been shown that oligodendrocyte-derived exosomes are taken up by microglia in an immunologically silent manner (27). This study also found that the exosome internalization was preferentially associated with inflammatory unresponsive microglia, which presented with low levels of HMCII. Moreover, we found that mRNA expression of IL-1β and TNF-α did not change in BV-2 cells after N2a-derived exosome uptake (data not shown). Further studies are needed; however, these data suggest that the neuron-derived exosomes can aid in clearing Ab by preventing proinflammatory reactions by microglia.

Other aggregate-prone proteins, including α-synuclein and prion protein, which cause Parkinson and Creutzfeldt-Jakob diseases, respectively, are also associated with neuronal exosomes (49, 50). A challenging subject of studies in the future will be determining whether exosomes are involved in the assembly of these proteins and in their clearance. We presume that when uptake/clearance activity of microglia decreases, secretion of exosomes bearing these proteins might provoke the pathological events, which substantially occur in the extracellular space. Indeed, in the absence of exosome-removing cells, exosomes associating with both normal and abnormally folded species of prion proteins are infectious, resulting in their spreading between neuronal cells (51, 52). Furthermore, secreted α-synuclein in association with exosomes causes cell death of recipient neuronal cells (50). Ab plaques might also be pathological structures built under lack of glial activity for removing exosomes. Actually, decreased numbers of microglia in a mouse model of AD result in increased Ab deposition (53).

Improvement of Ab clearance is a potent strategy for AD therapy (3). This study might provide a new approach using exosomes to aid in Ab elimination. Modulation of exosome secretion by selective regulation of the Cer-metabolizing pathway is likely therapeutically useful. In addition, delivery technology of exosomes, including the targeting of intravenously injected exosomes into the brain, has been developed for ther-
Exosome-mediated Aβ Clearance

apeutic applications (54). It might also be useful for exosome-mediated Aβ clearance in AD with some advantages, such as treatment with engineered exosomes or with required quantities of exosomes.

REFERENCES

1. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer disease. Progress and problems on the road to therapeutics. Science 297, 353–356
2. Selkoe, D. J. (1997) Alzheimer disease. Genotypes, phenotypes, and treatments. Science 275, 630–631
3. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., and Bateman, R. J. (2010) Decreased clearance of CNS β-amyloid in Alzheimer disease. Science 330, 1774
4. Bateman, R. J., Munsell, L. Y., Morris, J. C., Swann, R., Yarasheski, K. E., and Holtzman, D. M. (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856–861
5. Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., and Simons, K. (2006) Alzheimer disease β-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 103, 11172–11177
6. Simons, M., and Raposo, G. (2009) Exosomes. Vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21, 575–581
7. Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Caussé, C., Blot, B., Grange, J., Schoenh, G., Goldberg, Y., Boyer, V., Kirchhoff, F., Raposo, G., Garin, J., and Sadoul, R. (2006) Exosomes are released by cultured cortical neurones. Mol. Cell. Neurosci. 31, 642–648
8. Théry, C., Zitvogel, L., and Amigorena, S. (2002) Exosomes. Composition, biogenesis, and function. Nat. Rev. Immunol. 2, 569–579
9. de Gassart, A., Geminard, C., Fevrier, B., Raposo, G., and Vidal, M. (2003) A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 4894–4902
10. Levi, G., Aloisi, F., Ciotti, M. T., Thangnipon, W., Kingsbury, A., and Stolz, D. B., (2008) Formation of toxic Aβ-amyloid fibrils. J. Biol. Chem. 283, 680–685
11. Morelli, A. E., Larregina, A. T., Shufesky, W. J., Sullivan, M. L., Stolz, D. B., Papworth, G. D., Zahorchak, A. F., Logar, A. J., Wang, Z., Watkins, S. C., Falo, L. D., Jr., and Thomson, A. W. (2004) Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104, 3257–3266
12. Ariga, T., McDonald, M. P., and Yu, R. K. (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer disease. A review. J. Lipid Res. 49, 1157–1175
13. Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., Yamamoto, N., Michikawa, M., Yoshikawa, Y., Terao, K., Matsuzaki, K., Lemere, C. A., Selkoe, D. J., Naiki, H., and Yanagisawa, K. (2004) A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 4894–4902
14. Haass, C., and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration. Lessons from the Alzheimer amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112
15. Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B., and Simons, M. (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247
16. Luberto, C., and Hannun, Y. A. (1998) Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J. Biol. Chem. 273, 14550–14559
17. Napoli, L., and Neumann, H. (2009) Microglial clearance function in health and disease. Neuroscience 158, 1030–1038
18. Ransohoff, R. M. (2007) Microglial. The questions shape the answers. Nat. Neurosci. 10, 1507–1509
19. Faitzner, D., Schnaar, M., van Rossum, D., Krishnamoorthy, G., Dhaj, B., Bakhti, M., Regen, T., Hanisch, U. K., and Simons, M. (2011) Selective transfer of exosomes from oligodendrocytes to microglia by macrophocytosis. J. Cell Sci. 124, 447–458
20. Miyashita, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., and Nagata, S. (2007) Identification of Tim4 as a phosphatidylserine receptor. Nature 450, 435–439
21. Haughey, N. J., Bandaru, V. V., Bae, M., and Mattson, M. P. (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer disease neuro-pathogenesis. Biochim. Biophys. Acta 1801, 878–886
22. Kreutzberg, G. W. (1996) Microglia. A sensor for pathological events in the CNS. Trends Neurosci. 19, 312–318
23. Harper, J. D., and Lansbury, P. T., Jr. (1997) Models of amyloid seeding in Alzheimer disease and scrapie. Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407
24. Yamamoto, N., Matsubara, T., Sato, T., and Yanagisawa, K. (2008) Age-dependent high density clustering of GM1 ganglioside at presynaptic neurite terminals promotes amyloid β-peptide fibrillogenesis. Biochim. Biophys. Acta 1778, 2717–2726
25. Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M., and Matsuoka, K. (2008) Formation of toxic Aβ(1–40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in Aβ(1–40) fibrils. J. Biol. Chem. 382, 1066–1074
26. Goldsbury, C., Frey, P., Olivieri, V., Aebi, U., and Müller, S. A. (2005) Multiple assembly pathways underlie amyloid-β fibril polymorphisms. J. Mol. Biol. 352, 282–298
27. Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W. M., Mattson, M. P., and Tycko, R. (2005) Self-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrils. Science 307, 262–265
28. Sharple, R. A., Vella, L. J., Nisbet, R. M., Naylor, R., Perez, K., Barnham, K. J., Masters, C. L., and Hill, A. F. (2008) Inhibition of γ-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 22, 1469–1478
29. Takahashi, R. H., Mänter, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., and Gouras, G. K. (2002) Intranuclear Alzheimer ab β42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869–1879
30. Kimura, N., and Yanagisawa, K. (2007) Endosomal accumulation of GM1 ganglioside-bound amyloid β-protein in neurons of aged monkey brains. Neuroreport 18, 1669–1673
31. Liu, B., Hassler, D. F., Smith, G. K., Weaver, K., and Hannun, Y. A. (1998) Purification and characterization of a membrane-bound neutral pH optimum magnesium-dependent and phosphorylserine-stimulated sphingomyelinase from rat brain. J. Biol. Chem. 273, 34472–34479
32. Karakashian, A. A., Giliati, N. V., Smith, G. M., and Nikolova-Karakashian, M. N. (2004) Expression of neutral sphingomyelinase-2 (SMase-2) in primary rat hepatocytes modulates IL-β-induced iNKe-
41. Huitema, K., van den Dikkenberg, J., Brouwers, J. F., and Holthuis, J. C. (2004) Identification of a family of animal sphingomyelin synthases. *FASEB J.* **18**, 968–970
42. Tafesse, F. G., Ternes, P., and Holthuis, J. C. (2006) The multigenic sphingomyelin synthase family. *J. Biol. Chem.* **281**, 39421–29425
43. Gulbins, E., and Kolesnick, R. (2003) Raft ceramide in molecular medicine. *Oncogene* **22**, 7070–7077
44. Tam, C., Idone, V., Devlin, C., Fernandes, M. C., Flannery, A., He, X., Schuchman, E., Tabas, I., and Andrews, N. W. (2010) Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. *J. Cell Biol.* **189**, 1027–1038
45. Zha, X., Pierini, L. M., Leopold, P. L., Skiba, P. J., Tabas, I., and Maxfield, F. R. (1998) Sphingomyelinase treatment induces ATP-independent endocytosis. *J. Cell Biol.* **140**, 39–47
46. Majumdar, A., Cruz, D., Asamoah, N., Buxbaum, A., Sohar, I., Lobel, P., and Maxfield, F. R. (2007) Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. *Mol. Biol. Cell* **18**, 1490–1496
47. Cameron, B., and Landreth, G. E. (2010) Inflammation, microglia, and Alzheimer disease. *Neurobiol. Dis.* **37**, 503–509
48. Magnus, T., Chan, A., Grauer, O., Toyka, K. V., and Gold, R. (2001) Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. *J. Immunol.* **167**, 5004–5010
49. Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., and Raposo, G. (2004) Cells release prions in association with exosomes. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 9683–9688
50. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., and Vekrellis, K. (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. *J. Neurosci.* **30**, 6838–6851
51. Fèvrier, B., and Raposo, G. (2004) Exosomes. Endosomal-derived vesicles shipping extracellular messages. *Curr. Opin. Cell Biol.* **16**, 415–421
52. Vella, L. J., Sharples, R. A., Lawson, V. A., Masters, C. L., Cappai, R., and Hill, A. F. (2007) Packaging of prions into exosomes is associated with a novel pathway of PrP processing. *J. Pathol.* **211**, 582–590
53. El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat. Med.* **13**, 432–438
54. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., and Wood, M. J. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat. Biotechnol.* **29**, 341–345

**Exosome-mediated Aβ Clearance**

MARCH 30, 2012 • VOLUME 287 • NUMBER 14

"Exosome-mediated Aβ Clearance"